Absorption kinetics of misoprostol with oral or vaginal administration

被引:465
作者
Zieman, M
Fong, SK
Benowitz, NL
Banskter, D
Darney, PD
机构
[1] UNIV CALIF SAN FRANCISCO,SCH MED,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143
[2] UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,SAN FRANCISCO,CA 94143
[3] UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHARM,SAN FRANCISCO,CA 94143
[4] UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143
关键词
D O I
10.1016/S0029-7844(97)00111-7
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To compare the pharmacokinetics of vaginal and oral administration of the prostaglandin E-1 analogue, misoprostol. Methods: Twenty women received 400-mu g doses of misoprostol either orally or as tablets placed in the vagina. Serum levels of the principal metabolite, misoprostol acid, were measured at 7.5, 15, 30, 45, 60, 90, 120, and 240 minutes. The first ten women were pregnant and undergoing first-trimester abortions, and the last ten were not pregnant and had additional blood sampling at 360 minutes. We compared the pharmacokinetics of misoprostol acid after oral and vaginal administration. Results: All 20 subjects completed the study. The maximum mean (+/- standard deviation [SD]) of misoprostol acid differed significantly between the oral and vaginal groups (277 +/- 124 compared with 165 +/- 86 pg/mL, respectively; P = .03, analysis of variance), as did the mean a SD time to peak levels (34 +/- 17 compared with 80 +/- 27 minutes, respectively; P < .001) and areas under the misoprostol concentration versus time curve (mean +/- SD) up to 4 hours (n = 20, 273.3 +/- 110.0 compared with 503.3 +/- 296.7 pg.hour/mL, respectively; P = .033) and up to 6 hours (n = 10, 300.0 +/- 103.3 compared with 956.7 +/- 541.7 pg.hour/mL, respectively; P = .029). The extent of absorption was highly variable among subjects in each group. Conclusion: There are significant differences in the pharmacokinetics of misoprostol administered by vaginal and oral routes that may explain the difference observed in clinical efficacy. Assuming that the pharmacologic effect of misoprostol is related to its concentration in the plasma, our observation of the prolonged serum concentrations in the vaginal group suggests that vaginal administration could be dosed at longer intervals than oral. (C) 1997 by The American College of Obstetricians and Gynecologists.
引用
收藏
页码:88 / 92
页数:5
相关论文
共 19 条
[1]  
BUGALHO A, 1994, OBSTET GYNECOL, V83, P729
[2]   A COMPARATIVE-STUDY OF VAGINAL MISOPROSTOL AND INTRAVENOUS OXYTOCIN FOR INDUCTION OF LABOR [J].
BUGALHO, A ;
BIQUE, C ;
MACHUNGO, F ;
BERGSTROM, S .
GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 1995, 39 (04) :252-256
[3]   PREGNANCY INTERRUPTION BY VAGINAL MISOPROSTOL [J].
BUGALHO, A ;
BIQUE, C ;
ALMEIDA, L ;
BERGSTROM, S .
GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 1993, 36 (04) :226-229
[4]   Uterine evacuation by vaginal misoprostol after second trimester pregnancy interruption [J].
Bugalho, A ;
Bique, C ;
Pereira, C ;
Granja, AC ;
Bergstrom, S .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1996, 75 (03) :270-273
[5]   METHOTREXATE AND MISOPROSTOL FOR EARLY ABORTION [J].
CREININ, MD ;
DARNEY, PD .
CONTRACEPTION, 1993, 48 (04) :339-348
[6]   PREDILATATION OF THE CERVIX BEFORE SUCTION CURETTAGE FOR THERAPEUTIC-ABORTION IN EARLY-PREGNANCY [J].
EDWARDS, D ;
AITKEN, RE ;
BEGG, AF ;
MACKAY, PM ;
MARCHANT, RM .
AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 1994, 34 (01) :103-104
[7]  
ELRAFAEY, 1995, NEW ENGL J MED, V332, P983
[8]  
ELRAFAEY H, 1994, LANCET, V343, P1207
[9]  
ELRAFAEY H, 1994, CONTRACEPTION, V49, P111
[10]   Effect of vaginal misoprostol application for cervical softening in pregnancy interruption before ten weeks of gestation [J].
Ficicoglu, C ;
Tasdemir, M ;
Tasdemir, S .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1996, 75 (01) :54-56